glucose metabolism
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Healthy male/female daytime workers Age: 20-75 Education: High-school graduate level
Exclusion criteria
Exclusion criteria: Subjects who take mediations acting on glucose metabolism (Steroid, NSAIDS (non-steroid anti-inflammatory drugs), Anti-diabetes drugs) Those who have a risk of subcutaneous bleeding by inserting a continuous glucose monitoring (CGM) sensor
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome Measurements Daily glucose fluctuations by using a continuous glucose monitoring system (Freestyle Libre Pro, Abbot Diabetes Care Inc., USA, Japanese pharmaceutical approval: 22800BZX00227000). Glucose profiles are consistently measured during the 14-day test period. Measurement outcomes Basic glucose response: (a)Effective glucose peak value (Gp) from glucose baseline (b)net MAGE (mean amplitude of glucose excursion) Definition of Net MAGE MAGE was defined as the average of upward (MAGE(+)) and downward (MAGE(-)) excursions exceeding the standard deviation of glycemic excursion data over a day measured by CGM as follows: MAGE=(MAGE(+) + MAGE(-))/2 Glycemic excursion fluctuations can be evaluated by the upper and lower envelopes of excursion profiles. Net glycemic fluctuation amplitudes (net MAGE) defined for each glycemic peak as abs[G(i)-GN(i)], where G(i) and GN(i) are glucose peak and baseline value of the ith peak of the daily glucose excursion profile. | — |
Secondary
| Measure | Time frame |
|---|---|
| Glucose levels measured at every 15 minutes during study period of 14 days | — |
Countries
Japan
Contacts
The University of Tokyo Biosystems Engineering for Health and Longevity, Department of Bioengineering, School of Engineering